ACONITIC ACID, (Z)-

Possibly Marketed Outside US

Details

Stereochemistry	ACHIRAL
Molecular Formula	C6H6O6
Molecular Weight	174.1082
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(=O)C\C(=C\C(O)=O)C(O)=O

InChI

InChIKey=GTZCVFVGUGFEME-IWQZZHSRSA-N

InChI=1S/C6H6O6/c7-4(8)1-3(6(11)12)2-5(9)10/h1H,2H2,(H,7,8)(H,9,10)(H,11,12)/b3-1-

HIDE SMILES / InChI

Description
Sources: http://www.fda.gov/Food/IngredientsPackagingLabeling/GRAS/SCOGS/ucm260845.htm
Curator's Comment: description was created based on several sources, including: http://www.drugfuture.com/chemdata/Aconitic-Acid.html http://www.accessdata.fda.gov/spl/data/c8b036c1-1366-4707-8f26-5778fc3335b7/c8b036c1-1366-4707-8f26-5778fc3335b7.xml

Aconitic Acid found in leaves and tubers of Aconitum napellus L., Ranunculaceae, in various species of Achillea (Compositae) and Equisetum (Equisetaceae), in beet root, and in sugar cane. It is indicated for the temporary relief of symptoms of chronic illness including fatigue, effects of toxin buildup, slowed metabolism, weakened constitution. The limited data on trans-aconitic acid indicate it to be less toxic than citric acid. Trans-aconitate salts appear to be excreted readily by the kidneys. There is no direct evidence that trans-aconitic acid is utilized as is the cis-aconitic acid isomer in mammalian metabolism although non-specific oxidation probably occurs.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Glutamine synthetase 29 Target ID: CHEMBL4612 Sources: http://www.ncbi.nlm.nih.gov/pubmed/924365	Inhibitor 8297
response to oxidative stress 20 Target ID: GO:0006979 Sources: http://www.ncbi.nlm.nih.gov/pubmed/27507497	Modulator 828	70.0 mM [IC50]
aconitate decarboxylase 1 5 Target ID: 730249.0 Gene Symbol: ACOD1 Sources: http://www.ncbi.nlm.nih.gov/pubmed/26872335 \| http://www.genome.jp/dbget-bin/www_bget?ec:4.1.1.6	Substrate 661
Cytoplasmic aconitate hydratase 7 Target ID: P21399 Gene ID: 48.0 Gene Symbol: ACO1 Target Organism: Homo sapiens (Human) Sources: http://www.ncbi.nlm.nih.gov/pubmed/18139222 \| http://www.genome.jp/dbget-bin/www_bget?ec:4.2.1.3	Substrate 661
Leishmania donovani 13 Target ID: CHEMBL367 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8285634 \| https://www.ncbi.nlm.nih.gov/pubmed/2597432	Inhibitor 8297
Aconitase 5 Target ID: Aconitase Sources: https://www.ncbi.nlm.nih.gov/pubmed/2597432 \| https://www.ncbi.nlm.nih.gov/pubmed/28087696	Inhibitor 8297

Conditions

Condition	Modality	Highest Phase	Product
Fatigue 46 Sources: http://www.accessdata.fda.gov/spl/data/c8b036c1-1366-4707-8f26-5778fc3335b7/c8b036c1-1366-4707-8f26-5778fc3335b7.xml	Palliative	Approved 8429	IMMUNO-BOOST Approved Use GRAS. Homeopathic drug is indicated for the temporary relief of symptoms of chronic illness including fatigue, effects of toxin buildup, slowed metabolism, weakened constitution.
Toxin buildup 5 Sources: http://www.accessdata.fda.gov/spl/data/c8b036c1-1366-4707-8f26-5778fc3335b7/c8b036c1-1366-4707-8f26-5778fc3335b7.xml	Palliative	Approved 8429	IMMUNO-BOOST Approved Use GRAS. Homeopathic drug is indicated for the temporary relief of symptoms of chronic illness including fatigue, effects of toxin buildup, slowed metabolism, weakened constitution.
Slowed metabolism 5 Sources: http://www.accessdata.fda.gov/spl/data/c8b036c1-1366-4707-8f26-5778fc3335b7/c8b036c1-1366-4707-8f26-5778fc3335b7.xml	Palliative	Approved 8429	IMMUNO-BOOST Approved Use GRAS. Homeopathic drug is indicated for the temporary relief of symptoms of chronic illness including fatigue, effects of toxin buildup, slowed metabolism, weakened constitution.

PubMed

Title	Date	PubMed
Fatal lactic acidosis in a newborn attributable to a congenital defect of pyruvate dehydrogenase.	1976 Jan	813176
Abnormal carbohydrate metabolism in cerebrospinal fluid in Rett syndrome.	1994 Jan	8151077
Age-related reference values for urinary organic acids in a healthy Turkish pediatric population.	1994 Jun	8087979
Antiviral effects of milk proteins: acylation results in polyanionic compounds with potent activity against human immunodeficiency virus types 1 and 2 in vitro.	1996 Jun 10	8738428
Lactoferrin. Antiviral activity of lactoferrin.	1998	9781360
Abnormal substrate levels that depend upon mitochondrial function in cerebrospinal fluid from Alzheimer patients.	1998	9693263
Charge modification of plasma and milk proteins results in antiviral active compounds.	1999 Dec	10628656
Organic acids in the second morning urine in a healthy Swiss paediatric population.	2003 Dec	14708889
Characterization of organic anion-transporting polypeptide (Oatp) 1a1 and 1a4 null mice reveals altered transport function and urinary metabolomic profiles.	2011 Aug	21561886

Patents

Sample Use Guides

In Vivo Use Guide

10 drops under the tongue, 3 to 6 times per day

Route of Administration: Oral

In Vitro Use Guide

10-30 ug/ml of trans-aconitic acid inhibits TNF-α release in LPS-stimulated THP-1 cells up to75%

Name

Type

Language

ACONITIC ACID, (Z)-

Common Name

English

FEMA NO. 2010, Z-

Code

English

1-PROPENE-1,2,3-TRICARBOXYLIC ACID, (1Z)-

Common Name

English

CIS-ACONITIC ACID

Common Name

English

(Z)-1-PROPENE-1,2,3-TRICARBOXYLIC ACID

Systematic Name

English

NSC-227901

Code

English

ACONITIC ACID, CIS-

Common Name

English

CIS-PROPENE-1,2,3-TRICARBOXYLIC ACID

Common Name

English

Code System Code Type Description

ECHA (EC/EINECS)

209-564-4